BioAge Labs, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by BioAge Labs, Inc. on June 10, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol BIOA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Corporate Actions
Stockholders approved two key proposals at the annual meeting:
- Director Elections: Three Class II Directors were elected to three-year terms expiring at the 2029 Annual Meeting: Patrick Enright, M.B.A., James I. Healy, M.D., Ph.D., and Rekha Hemrajani, M.B.A.
- Auditor Ratification: The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
Voting Results
| Proposal / Nominee | For | Against / Withheld | Abstaining / Non-Votes |
|---|---|---|---|
| Patrick Enright | 30,075,928 | 1,184,271 | 5,327,405 (Broker Non-Votes) |
| James I. Healy | 25,499,205 | 5,760,994 | 5,327,405 (Broker Non-Votes) |
| Rekha Hemrajani | 27,826,781 | 3,433,418 | 5,327,405 (Broker Non-Votes) |
| KPMG LLP Ratification | 36,561,171 | 1,305 | 25,128 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the election of the three new Class II members.
- Confirm the engagement of KPMG LLP for the 2026 fiscal year audit.
- Note the significant number of broker non-votes (5,327,405) recorded for all director nominees.
- Review the company's upcoming 10-K or 10-Q filings for financial metrics absent from this 8-K.